Download presentation
Presentation is loading. Please wait.
Published byJean-François Aubin Modified over 6 years ago
1
Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy by Gabriel Etienne, Nicolini E Nicolini, Stéphanie Dulucq, Anna Schmitt, Sandrine Hayette, Éric Lippert, Isabelle Tigaud, Stephane Morisset, Caroline Bureau, Didier Adiko, Gerald Marit, Josy Reiffers, and Francois-Xavier Mahon Blood Volume 120(21): November 16, 2012 ©2012 by American Society of Hematology
2
Event-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy. Event-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy. Gabriel Etienne et al. Blood 2012;120:3754 ©2012 by American Society of Hematology
3
Progression-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy. Progression-free survival of patients who achieved CCyR without MMR (n=23) (CCyR+MMR-), CCyR with MMR without CMR (n=92) (CCyR+MMR+CMR-) and CCyR with CMR (n=65) (CCyR+MMR+CMR+) on IM therapy. Gabriel Etienne et al. Blood 2012;120:3754 ©2012 by American Society of Hematology
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.